case / 11 Aug 2020

Setterwalls advises Saniona in connection with directed issue of approximately SEK 567 million

Responsive image

Setterwalls has advised Saniona AB in connection with a directed issue to a number of U.S. and international institutional investors and sector specialists.

Saniona AB, a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system, has carried out a directed issue that provides the company with gross proceeds of USD 65 million (approximately SEK 567 million). The new issue was directed to a number of U.S. and international institutional investors and sector specialists.

The issue proceeds will be used to continue Saniona’s advancement of its late-stage clinical trials with the product candidate Tesomet in two rare eating disorders, hypothalamic obesity and Prader Willi Syndrome, as well as to build its U.S.-based organization in support of the company’s clinical development programs.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.